| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SMARCA2; BAF190B; BRM; SNF2A; SNF2L2; Probable global transcription activator SNF2L2; ATP-dependent helicase SMARCA2; BRG1-associated factor 190B; BAF190B; Protein brahma homolog; hBRM; SNF2-alpha; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 |
| Entrez GeneID | 6595 |
| WB Predicted band size | Calculated MW: 181 kDa; Observed MW: 181 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Brm. AA range:1328-1377 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于BRM(SMARCA2)抗体的3篇代表性文献摘要：
---
1. **标题**：*Targeting BRM/SMARCA2 in cancer: synthetic lethality and therapeutic implications*
**作者**：Romero OA et al.
**摘要**：研究探讨了BRM在癌症中的功能缺失及其与SMARCA4突变的合成致死效应，利用特异性抗体验证了BRM蛋白在肺癌细胞中的表达缺失，为靶向治疗提供依据。
---
2. **标题**：*Development and validation of a monoclonal antibody for SWI/SNF complex subunit SMARCA2*
**作者**：Wang X et al.
**摘要**：报道了一种高特异性的BRM单克隆抗体的开发与验证，通过免疫印迹和免疫组化证实其在检测染色质重塑复合体中的可靠性，适用于癌症诊断研究。
---
3. **标题**：*Epigenetic regulation by BRM governs lineage plasticity in pancreatic cancer*
**作者**：Dagogo-Jack I et al.
**摘要**：研究揭示BRM通过调控染色质可塑性影响胰腺癌分化状态，利用BRM抗体进行ChIP-seq分析，发现其结合靶基因启动子区域并抑制肿瘤干细胞特性。
---
这些文献覆盖了BRM抗体的开发、功能研究及在癌症机制中的应用，可作为相关研究的参考。
BRM (Brahma) antibodies are essential tools for studying the SMARCA2 gene product, a key ATPase subunit of the SWI/SNF chromatin-remodeling complex. The SWI/SNF complex regulates gene expression by altering nucleosome positioning, enabling access to transcription factors. BRM works in tandem with its homolog BRG1 (SMARCA4) to control cellular processes like proliferation, differentiation, and DNA repair. Dysregulation of BRM is implicated in cancer, as its loss or mutation disrupts tumor-suppressive functions and promotes oncogenesis in lung, blood, and other cancers.
BRM antibodies are widely used in research to investigate epigenetic mechanisms, chromatin dynamics, and cancer biology. They enable detection of BRM expression levels via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Specific antibody clones (e.g., anti-SMARCA2 antibodies) help distinguish BRM from BRG1. which share functional redundancy but have distinct roles in tissue-specific contexts. Validated antibodies are critical for studies exploring SWI/SNF complex alterations in diseases, including synthetic lethality approaches targeting BRM-deficient cancers.
Recent studies also highlight BRM's role in immune regulation and metabolic pathways, expanding its therapeutic relevance. Commercial BRM antibodies are typically raised against conserved epitopes, with validation data confirming specificity in knockout controls. Researchers must select antibodies verified for their intended applications, as SWI/SNF proteins exhibit tissue-specific isoform expression. Overall, BRM antibodies remain indispensable for unraveling chromatin remodeling mechanisms and developing targeted epigenetic therapies.
×
